CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.

Slides:



Advertisements
Similar presentations
NANC Report Numbering Oversight Working Group (NOWG) May 13, 2003 Co-Chairs: Karen Mulberry, MCI Jim Castagna, Verizon.
Advertisements

Tips to a Successful Monitoring Visit
Adverse Events and Serious Adverse Events
ACRIN Fall Meeting 2009 ACRIN Adverse Event Reporting Manual Revisions Presented by: Cornelia Tsikos, BS, MS.
Common Terminology Criteria for Adverse Events (CTCAE) v.4: Updating a Cancer Research Standard Ann Setser 1, Ranjana Srivastava 2, Lawrence Wright 1,
Quality Management within the Clinical Research Process
Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.
PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.
COURSE PROPOSAL: METHODS IN CLINICAL CANCER RESEARCH Primary Instructor: Elizabeth Garrett-Mayer, PhD Professor of Biostatistics, Dept. of Public Health.
Standardisation of Trial Design Definitions in CDW at Novo Nordisk
Cancer Clinical Trials: The Basics. 2 What Are Cancer Clinical Trials? Research studies involving people Try to answer scientific questions and find better.
Using EDC-Rave to Conduct Clinical Trials at Genentech
Clinical Data Management is involved in all aspects of processing the clinical data, working with a range of computer applications, database systems.
Tracking Protocol Development Timelines Steve Friedman, MHSA Chief, Clinical Trials Operations and Informatics Branch.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
NCI Clinical Trials Reporting Program CTRP User Meeting May 2, 2012 Gene Kraus CTRP Program Director.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Auditing & Quality Assurance Igor Espinoza-Delgado, M.D. Gary Smith M.Sc. Cancer Therapy Evaluation Program.
NCI-sponsored treatment trials: CTCAE v4 790 individual items Standard Approach to AE Monitoring CATEGORYEXAMPLEDATA SOURCE LaboratoryNeutropeniaLaboratory.
Response to FDA Audit 483 MX-4501N : Nine Category 483 Citations Meetings Minutes: Votes for, against, abstention and reason not recorded;
ArtClinica Address: 1175 Marlkress Rd, #2632, Cherry Hill, NJ 08034, USAPhone: Fax: ARTClinica.
Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,
Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Cancer Clinical Trial Suite (CCTS): An Introduction for Users A Tool Demonstration from caBIG™ Bill Dyer (NCI/Pyramed Research) June 2008.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Integrating the Healthcare Enterprise Teaching File and Clinical Trial Export John Perry Fujifilm Medical Systems IHE Planning Committee.
PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Amy P. Abernethy, MD Task 6: Usability.
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Cancer Center Administration Database.
Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility)
Dave Iberson-Hurst CDISC VP Technical Strategy
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Investigator’s Meeting
Using EDC-Rave to Conduct Clinical Trials at Genentech Susanne Prokscha Principal CDM PTM Process Analyst February 2012.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
NCI Clinical Trials Reporting Program CTRP User Meeting October 6, 2010.
CTRP User Call November 13, 2013 Gene Kraus CTRP Program Director.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
CTRP User Call May 7, 2014 Gene Kraus CTRP Program Director.
Sandra A. Mitchell, PhD, CRNP Outcomes Research Branch, DCCPS
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
1 Dianne Reeves VCDE Presentation December 15, 2011 NCI caBIG® CRF Standards use in NCI CDMS MediData Rave.
UNIT-II CLINICAL DATA. UNIT-II CLINICAL DATA: Clinical Data, Application, Challenges, Solutions, Clinical Data Management System.
Subject Registrations Adverse Events Subject Registrations Biospecimens Lab Results IN: 1. Lab Results OUT: 1. Subject Registrations 2. Clinical Notes.
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
SAGE Nick Beard Vice President, IDX Systems Corp..
NCI Clinical Trials Reporting Program CTRP User Meeting June 6, 2012 Gene Kraus CTRP Program Director.
No Conflicts of Interest Including the Patient Voice in Safety Reporting Ethan Basch, MD, MSc Health Outcomes Group Departments of Medicine and Epidemiology/Biostatistics.
Radiation Therapy Trials - Quality Assurance:  patient safety  adherence to protocol constraints  uniformity of patient treatments  efficient review.
NCI Clinical Trials Reporting Program CTRP User Meeting May 4, 2011.
May 2007 CTMS / Imaging Interoperability Scenarios March 2009.
Session 6: Data Flow, Data Management, and Data Quality.
Medidata Rave Start-Up Information
STUDY RESOURCES 1. OVERVIEW OF STUDY RESOURCES Study documents Study overview documents (project overview, data requirements.
11 Radiation Therapy Oncology Group Clinical Trials Administration Sharon Hartson Stine, Director Group Administrator.
Safety in Practice Langimalie Integrated Family Health Centre Warfarin Management Panmure Onehunga.
June 28-29, 2005IHE Interoperability Workshop 1 Integrating the Healthcare Enterprise Teaching File and Clinical Trial Export John Perry Fujifilm Medical.
Submission Standards: The Big Picture Gary G. Walker Associate Director, Programming Standards, Global Data Solutions, Global Data Management.
1 SAE Centralized Report and Review Process April 2012.
Data Management: Source Documents, Case Report Forms and Electronic Data Thomas Salerno, RN BSN MA Senior Team Lead Cardiology Research Jefferson Clinical.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
HERO Patient Navigation Arm
Design of Case Report Forms
Dave Iberson-Hurst CDISC VP Technical Strategy
11 ii. Develop a plan for aDSM
Electronic Health Records
Serious Adverse Event Reconciliation
Presentation transcript:

CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010

Agenda Conceptual overview of NCI AE reporting CTEP Adverse Event Reporting Systems – Multiple mechanisms for AE data submission Routine via CTMS; CDUS; CDS Expedited via AdEERS AE Reporting Workflow – Variable practices Issues to consider for integration of PRO- CTCAE

NCI AE Reporting Overview Methodology varies widely among sites, modalities, specialties, practices There are no guidelines or uniform methods for how to capture, present and interpret AE data Within NCI, requirements differ – Paper CRF – Multiple data systems (Groups, Centers, CTEP, contractors, others) At the patient encounter, most clinician- documented AE / symptom data are not CTCAE terms and often include notes that do not promote straightforward translation to CTCAE Grade (severity indicator)

NCI AE Reporting Overview… From patient encounter to sponsor analysis and publication, many layers of ‘interpretation and translation’ of AE terms and severity indicators occur. CTCAE data is a collection of secondary endpoints used to generate an overall picture or general safety profile of a given treatment, to identify gross trends and differences between studies, arms, groups, etc.

CTEP Adverse Event Reporting Systems 1.Clinical Data Update System CDUS Primary resource of clinical trial data for NCI DCTD and DCP Types of Data Sets – Abbreviated CDUS (Phase 3 - no AE data) – Complete CDUS (Phase 1, 2 AE data) Methods of Data Submission – ftp data transfer – web Contents of data set – Cumulative data per protocol

CTEP Adverse Event Reporting Systems… CDUS Data Submission Early Phase 1 – via CTMS (Clinical Trials Monitoring System) File Transfer Protocol (FTP) Monthly Other Phase trials: – via CDUS Lead Group or Lead Institution submits data set FTP or web Quarterly

Adverse Events Screen

Steps

CTEP Adverse Event Reporting Systems…AdEERS Adverse Event Expedited Reporting System Expedited AE reporting tool for CTEP sponsored trials Expedited reporting (AdEERS) is always in addition to Routine Reporting All AEs (meeting the CDUS reporting requirements) must be submitted as part of routine reporting AdEERS does not replace Routine Reporting

CTEP Expedited AE Reporting AdEERS CTEP-specific rules as a sponsor reporting to FDA The foundation of AdEERS is CTCAE – Unlike industry (verbatim coded to MedDRA) AdEERS ‘rules’ based on CTCAE depend on Phase of Trial

Example: CTEP AdEERS ‘Rules’

CTEP Expedited AE Reporting AdEERS Because of timeline requirements, AdEERS data is usually closer to patient encounter Requires extensive patient level data entry each time a report is generated Data reviewed by CTEP almost real-time – 24 hours – 5 days – 10 days Next slide: Screensnap of AdEERS with Sections of Report

Screensnap of AdEERS with Sections of Report

CDUS-reported and AdEERS-reported AEs 1.Design and expectations of two systems are very different CDUS = summary cumulative AE data by quarter AdEERS = detailed AE data in real-time 2. Initially there was no expectation for comparison of data from the two systems Programmatic data element requirements differ Different staff with different AE expertise submit to the different systems 3. AdEERS-CDUS Reconciliation implemented April 1, 2006 Comparison of the data reported to the 2 systems All Grade 5 discrepancies must be resolved All other discrepancies result in a CDUS caution

Workflow Processes for reporting Routine AEs - Paper 1.At the patient encounter clinician documents AEs / symptoms – On paper Patient chart / Progress Note Trial-specific ‘cheat sheet’ / AE CRF – Electronic Electronic Health Record Remote Data Capture System 2.Nurse, CRA, or Data Manager retrospectively reviews source data – Translates symptoms into CTCAE terms and grades and transcribes onto trial-specific AE CRF

Workflow Processes for reporting Routine AEs - Paper… 3.Site personnel submit paper CRF to Cooperative Group or Lead Organization 4.Cooperative Group or Lead Organization personnel enter AE data into data system 5.Technical staff prepare and submit electronic data to CTEP via CDUS ftp

Workflow Processes for reporting Routine AEs - Electronic… 1.Site access to RDC, CDMS, etc. 2.Site technical staff program local data file transfer to Group data system 3.Group technical staff prepare CTEP- required subset of all Group data and reprograms for submission to CTEP CDUS

Going Forward with PRO-CTCAE 1.Understand strengths and limitations of current AE data systems and processes—from patient encounter to sponsor to regulators to publication 2.With awareness of the varied processes (paper, electronic), how best might PROs be integrated and help achieve more real-time AE reporting? 3.How will PRO data be analyzed / utilized relative to clinician-reported AE data? 4.How can we achieve a common method to summarize and communicate overall AE burden?

Acronyms AdEERSAdverse Event Expedited Reporting System CDUSClinical Data Update System (FTP submission) CDSClinical Data System (Web submission) CDMSClinical Data Management System CTCAECommon Terminology Criteria for Adverse Events CTEPCancer Therapy Evaluation Program CRAClinical Research Associate CRFCase Report Form CTMSClinical Trials Monitoring System DCPDivision of Cancer Prevention DCTDDivision of Cancer Treatment and Diagnosis FTPFile Transfer Protocol RDCRemote data capture

Discussion